DK0784483T3 - Præparat indeholdende et rekombinant virus, der udtrykker et antigen, og et rekombinant virus, der udtrykker et immunstimul - Google Patents

Præparat indeholdende et rekombinant virus, der udtrykker et antigen, og et rekombinant virus, der udtrykker et immunstimul

Info

Publication number
DK0784483T3
DK0784483T3 DK95935264T DK95935264T DK0784483T3 DK 0784483 T3 DK0784483 T3 DK 0784483T3 DK 95935264 T DK95935264 T DK 95935264T DK 95935264 T DK95935264 T DK 95935264T DK 0784483 T3 DK0784483 T3 DK 0784483T3
Authority
DK
Denmark
Prior art keywords
recombinant virus
virus expressing
antigen
composition containing
immune stimulus
Prior art date
Application number
DK95935264T
Other languages
Danish (da)
English (en)
Inventor
Judith Kantor
Jeffrey Schlom
James W Hodge
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/483,316 external-priority patent/US6045802A/en
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of DK0784483T3 publication Critical patent/DK0784483T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46448—Cancer antigens from embryonic or fetal origin
    • A61K39/464482—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK95935264T 1994-10-03 1995-10-02 Præparat indeholdende et rekombinant virus, der udtrykker et antigen, og et rekombinant virus, der udtrykker et immunstimul DK0784483T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31726894A 1994-10-03 1994-10-03
US08/483,316 US6045802A (en) 1994-10-03 1995-06-07 Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
PCT/US1995/012624 WO1996010419A2 (en) 1994-10-03 1995-10-02 Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule

Publications (1)

Publication Number Publication Date
DK0784483T3 true DK0784483T3 (da) 2001-03-26

Family

ID=26980864

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95935264T DK0784483T3 (da) 1994-10-03 1995-10-02 Præparat indeholdende et rekombinant virus, der udtrykker et antigen, og et rekombinant virus, der udtrykker et immunstimul

Country Status (12)

Country Link
US (3) US6548068B1 (ja)
EP (2) EP1016418B1 (ja)
JP (3) JP3907698B2 (ja)
AT (1) ATE197765T1 (ja)
AU (1) AU688606B2 (ja)
CA (1) CA2201587C (ja)
DE (1) DE69519521T2 (ja)
DK (1) DK0784483T3 (ja)
ES (1) ES2154738T3 (ja)
GR (1) GR3035458T3 (ja)
PT (1) PT784483E (ja)
WO (1) WO1996010419A2 (ja)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994024267A1 (en) * 1993-04-20 1994-10-27 Robinson, William, S. Methods and materials for treatment of individuals infected with intracellular infectious agents
AU731860B2 (en) * 1996-07-25 2001-04-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Recombinant pox virus for immunization against tumor-associated antigens
WO1998004728A1 (en) * 1996-07-25 1998-02-05 Therion Biologics Corporation Recombinant pox virus for immunization against tumor-associated antigens
EP1012276A2 (en) 1997-02-24 2000-06-28 Therion Biologics Corporation Recombinant pox virus for immunization against muc1 tumor-associated antigen
US6730512B2 (en) * 1997-04-09 2004-05-04 Amdl, Inc. Combination immunogene therapy
TW586934B (en) * 1997-05-19 2004-05-11 Sumitomo Pharma Immunopotentiating composition
JP2001515052A (ja) * 1997-08-13 2001-09-18 ザ ユーエイビー リサーチ ファンデーション 遺伝子ベクターの局所施用によるワクチン接種
US6969609B1 (en) 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
DK1829551T3 (da) * 1998-02-20 2011-01-24 Univ Miami Modificeret varmchokprotein-antigenpeptid-kompleks
CN100352930C (zh) * 1998-02-27 2007-12-05 宾夕法尼亚州立大学托管会 疫苗、免疫治疗剂及其应用方法
US7279168B2 (en) 1998-05-01 2007-10-09 Texas A & M University System Recombinant virus expressing foreign DNA encoding feline CD86 and uses thereof
PL199352B1 (pl) * 1998-05-01 2008-09-30 Schering Plough Ltd Izolowane kwasy nukleinowe, oligonukleotyd, wektory, wektory plazmidowe, komórka gospodarza, polipeptydy, sposób wytwarzania polipeptydu, szczepionka, zastosowania szczepionki i zastosowania polipeptydu
UA73718C2 (en) * 1998-05-01 2005-09-15 Schering Plough Ltd Therapeutic vector expressing foreign dna, coding cat's cd80, cat's cd86, cat's cd28 or cat's ctla-4 and use thereof
ATE361988T1 (de) * 1998-12-09 2007-06-15 Us Gov Health & Human Serv Recombinanter vector, welcher mehrere kostimulatorische moleküle exprimiert und dessen verwenden
EP1865065A1 (en) * 1998-12-09 2007-12-12 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services A recombinant vector expressing multiple costimulatory molecules and uses thereof
AU6801800A (en) * 1999-08-30 2001-03-26 Ludwig Institute For Cancer Research Isolated nona and decapeptides which bind to hla molecules, and the use thereof
WO2001024832A2 (de) * 1999-09-27 2001-04-12 Gabriele Pecher Pharmazeutische zusammensetzung zur behandlung und prophylaxe von humanen tumoren, die das tumorantigen muzin und/oder das carcinoembryonale antigen (cea) exprimieren und ihre verwendung
JP2003510341A (ja) * 1999-10-06 2003-03-18 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 細胞ターゲッティング組成物及びそれらを使用する方法
DE60038971D1 (de) 1999-10-22 2008-07-03 Aventis Pasteur Verfahren zur erregung und/oder verstärkung der immunantwort gegen tumorantigene
EP1282702B1 (en) * 2000-05-10 2006-11-29 Sanofi Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
GB0111442D0 (en) * 2001-05-10 2001-07-04 Isis Innovation Method for preparing recombinant virus
US20030148973A1 (en) * 2001-05-23 2003-08-07 Peter Emtage MAGE-A1 peptides for treating or preventing cancer
US20040091995A1 (en) * 2001-06-15 2004-05-13 Jeffrey Schlom Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
EP1281767A3 (en) * 2001-07-31 2003-05-28 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of tumors
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
EP1864691B1 (en) 2002-04-09 2011-07-20 Sanofi Pasteur Limited Modified CEA nucleic acid and expression vectors
US20030228261A1 (en) * 2002-06-05 2003-12-11 Aladar Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
EP1369491A1 (en) * 2002-06-05 2003-12-10 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
US20040101522A1 (en) * 2002-09-12 2004-05-27 Therion Biologics Corporation Transduced neoplastic cell preparations able to express T-cell costimulatory molecules B7.1, ICAM-1, and LFA-3 and induce immunostimulatory prophylactic and therapeutic anti-tumor effects in-vivo
EP1556082A1 (en) * 2002-10-22 2005-07-27 Aventis Pasteur Limited Anti-cancer vaccines and high-dose cytokines as adjuvants
US8207314B2 (en) * 2003-05-16 2012-06-26 Sanofi Pasteur Limited Tumor antigens for prevention and/or treatment of cancer
CN100562570C (zh) * 2003-06-18 2009-11-25 吉恩勒克斯公司 修饰的重组痘苗病毒及其它微生物,及其应用
WO2005005465A2 (en) * 2003-07-08 2005-01-20 Board Of Regents, University Of Texas System Methods and compositions to enhance immune responses via recall antigens
CA2550583C (en) * 2003-10-08 2013-01-15 Sanofi Pasteur, Inc. Modified cea /b7 vector
JP5060134B2 (ja) 2003-12-12 2012-10-31 ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ・アズ リプレゼンテッド バイ ザ セクレタリー・デパートメント オブ ヘルス アンド ヒューマン サービシーズ ヒト細胞傷害性Ｔリンパ球のエピトープ及びそのＭＵＣ−１の非ＶＮＴＲ（ｎｏｎ−ｖａｒｉａｂｌｅｎｕｍｂｅｒｏｆｔａｎｄｅｍｒｅｐｅａｔｓｅｑｕｅｎｃｅ）由来のアゴニストエピトープ
US8012468B2 (en) * 2004-06-11 2011-09-06 Catholic Universtiy Industry Academic Cooperation Foundation Dendrite cells transduced with recombinant adenovirus AdVCEA which generate CEA-specific cytotoxic T lymphocytes, vaccine and pharmaceutical composition comprising the same
PT1990410T (pt) 2006-02-22 2020-03-03 Riken Imunoterapia por utilização de uma célula capaz de co-expressar um antigénio alvo e cd1d e pulsada com um ligando de cd1d
AU2007221255B2 (en) * 2006-02-24 2012-03-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunogenic peptides and methods of use
CN101438166A (zh) 2006-03-14 2009-05-20 俄勒冈健康科学大学 产生针对结核病的免疫应答的方法
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
US20090098529A1 (en) * 2006-10-16 2009-04-16 Nanhai Chen Methods for attenuating virus strains for diagnostic and therapeutic uses
DK2918598T3 (en) 2007-02-28 2019-04-29 The Govt Of U S A As Represented By The Secretary Of The Dept Of Health And Human Services Brachyury polypeptides and methods of use
US20090117034A1 (en) * 2007-06-15 2009-05-07 Nanhai Chen Microorganisms for imaging and/or treatment of tumors
US20090162288A1 (en) * 2007-07-18 2009-06-25 Nanhai Chen Use of modified vaccinia virus strains in combination with a chemotherapeutic agent for use in therapeutic methods
WO2009114085A2 (en) 2008-03-03 2009-09-17 The University Of Miami Allogeneic cancer cell-based immunotherapy
US8815564B2 (en) 2008-03-14 2014-08-26 Sanofi Pasteur Biologics, Llc Replication-defective flavivirus vaccines and vaccine vectors
CN102036677A (zh) 2008-03-20 2011-04-27 迈阿密大学 热休克蛋白gp96的疫苗接种及其使用方法
WO2010005474A1 (en) * 2008-06-16 2010-01-14 Emergent Product Development Gaithersburg Inc. Recombinant modified vaccinia virus ankara (mva) expressing chlamydia polypeptide antigens
JPWO2010061930A1 (ja) 2008-11-28 2012-04-26 独立行政法人理化学研究所 ＣＤ１ｄ及び標的抗原の共発現アロ細胞を用いた免疫療法
DE102008055194A1 (de) 2008-12-30 2010-07-08 Federal-Mogul Wiesbaden Gmbh Gleitelement
US8664183B2 (en) 2009-02-27 2014-03-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services SPANX-B polypeptides and their use
JP5759980B2 (ja) * 2009-04-17 2015-08-05 グローブイミューン，インコーポレイテッド 癌および感染症に対する免疫療法組成物の組み合わせ
US9173930B2 (en) 2009-11-20 2015-11-03 Oregon Health & Science University Methods for detecting a mycobacterium tuberculosis infection
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
WO2011129379A1 (ja) 2010-04-13 2011-10-20 独立行政法人理化学研究所 新規抗ｈｓｐ９０モノクローナル抗体
WO2011154476A1 (en) * 2010-06-10 2011-12-15 Intervet International B.V. Anti-tumor composition
DK2601529T3 (en) 2010-08-06 2017-03-27 Us Health Biomarkers for predicting the response to a cancer vaccine
JP2014510721A (ja) 2011-02-15 2014-05-01 イミューン デザイン コーポレイション ベクターワクチンによる免疫原特異的免疫応答を強化するための方法
MX350795B (es) 2011-04-08 2017-09-19 Inmune Design Corp Composiciones inmunogenicas y metodos para utilizar las composiciones para inducir respuestas inmunes humorales y celulares.
US11149254B2 (en) 2011-04-15 2021-10-19 Genelux Corporation Clonal strains of attenuated vaccinia viruses and methods of use thereof
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
PL2850431T3 (pl) 2012-05-16 2018-09-28 Immune Design Corp. Szczepionki przeciwko HSV-2
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
EP2895191B1 (en) 2012-09-14 2019-06-05 The U.S.A. as represented by the Secretary, Department of Health and Human Services Brachyury protein, adenoviral vectors encoding brachyury protein, and their use
WO2014140938A2 (en) 2013-03-14 2014-09-18 Centre Hospitalier Universitaire Vaudois Immunological methods
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3542816A1 (en) 2014-02-14 2019-09-25 Immune Design Corp. Immunotherapy of cancer through combination of local and systemic immune stimulation
EP3169352A1 (en) 2014-07-15 2017-05-24 Immune Design Corp. Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
ES2845727T3 (es) 2015-02-06 2021-07-27 Heat Biologics Inc Vector que coexpresa una vacuna y moléculas coestimuladoras
CN115300622A (zh) 2015-02-25 2022-11-08 纪念斯隆-凯特琳癌症中心 使用灭活的修饰的痘苗病毒安卡拉作为实体肿瘤的单一免疫疗法或与免疫检查点阻断剂组合
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3283088A4 (en) 2015-04-17 2018-10-24 Memorial Sloan-Kettering Cancer Center Use of mva or mvadeltae3l as immunotherapeutic agents against solid tumors
DK3294329T3 (da) * 2015-05-15 2020-05-04 Reber Genetics Co Ltd Hidtil ukendte baculovirusvektorer og fremgangsmåder til anvendelse
US11365230B2 (en) 2015-11-09 2022-06-21 Immune Design Corp. Compositions comprising lentiviral vectors expressing IL-12 and methods of use thereof
US20190183870A1 (en) 2016-01-05 2019-06-20 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Combination of histone deacetylase inhibitor and immunotherapy
WO2017136342A1 (en) 2016-02-02 2017-08-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells
JP2019509275A (ja) 2016-02-23 2019-04-04 イミューン デザイン コーポレイション マルチゲノムレトロウイルスベクター調製物ならびにそれらを産生および使用するための方法およびシステム
JP7025339B2 (ja) 2016-02-25 2022-02-24 メモリアル スローン ケタリング キャンサー センター 癌免疫療法のための、チミジンキナーゼの欠失を伴い、ヒトｆｌｔ３ｌまたはｇｍ－ｃｓｆの発現を伴うかまたは伴わない、複製可能な弱毒化ワクシニアウイルス
SG11201807022XA (en) 2016-02-25 2018-09-27 Memorial Sloan Kettering Cancer Center Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors
EP3442999A2 (en) 2016-04-15 2019-02-20 Alpine Immune Sciences, Inc. Icos ligand variant immunomodulatory proteins and uses thereof
MA43552A (fr) 2016-04-15 2018-11-07 Alpine Immune Sciences Inc Protéines immunomodulatrices à variants de cd80 et leurs utilisations
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
CA3032120A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
CA3040123A1 (en) 2016-10-11 2018-04-19 University Of Miami Vectors and vaccine cells for immunity against zika virus
BR112019018747A2 (pt) 2017-03-16 2020-05-05 Alpine Immune Sciences Inc proteínas imunomoduladoras variantes de cd80 e usos das mesmas
EP3596115A1 (en) 2017-03-16 2020-01-22 Alpine Immune Sciences, Inc. Pd-l2 variant immunomodulatory proteins and uses thereof
FI3596116T3 (fi) 2017-03-16 2023-11-09 Alpine Immune Sciences Inc Immunomodulatorisia pd-l1-varianttiproteiineja ja niiden käyttöjä
SG11201908280SA (en) 2017-03-30 2019-10-30 Univ Queensland "chimeric molecules and uses thereof"
US11548930B2 (en) 2017-04-04 2023-01-10 Heat Biologics, Inc. Intratumoral vaccination
WO2018209315A1 (en) 2017-05-12 2018-11-15 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy
KR20230020022A (ko) 2017-10-10 2023-02-09 알파인 이뮨 사이언시즈, 인코포레이티드 Ctla-4 변이체 면역조절 단백질 및 이의 용도
AU2018351000B2 (en) 2017-10-18 2023-11-30 Alpine Immune Sciences, Inc. Variant ICOS Ligand immunomodulatory proteins and related compositions and methods
BR112020013236A2 (pt) 2018-01-03 2020-12-01 Alpine Immune Sciences, Inc. proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso
CN111684198B (zh) * 2018-02-09 2022-09-23 株式会社龙野 填充装置
US20210363219A1 (en) 2018-06-15 2021-11-25 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
US20220177587A1 (en) 2018-09-19 2022-06-09 Alpine Immune Sciences, Inc. Methods and uses of variant cd80 fusion proteins and related constructs
US20220372106A1 (en) 2018-11-30 2022-11-24 Alpine Immune Sciences, Inc. Cd86 variant immunomodulatory proteins and uses thereof
WO2020214867A1 (en) 2019-04-17 2020-10-22 Alpine Immune Sciences, Inc. Methods and uses of variant icos ligand (icosl) fusion proteins
US20220313761A1 (en) 2019-05-14 2022-10-06 National University Corporation Tottori University Vaccinia virus that induces cell fusion and use thereof
EP4011389A1 (en) 2019-08-09 2022-06-15 Riken Combined use of artificial adjuvant vector cells and an immunostimulant
MX2022013998A (es) 2020-05-08 2023-02-16 Alpine Immune Sciences Inc Proteinas inmunomoduladoras inhibidoras de april y baff con y sin una proteina inhibidora de celulas t y metodos de uso de las mismas.
JPWO2022107705A1 (ja) 2020-11-17 2022-05-27
WO2022230971A1 (ja) 2021-04-30 2022-11-03 国立研究開発法人理化学研究所 コロナウイルスに対する免疫応答を誘発する人工アジュバントベクター細胞、および当該細胞を含む医薬組成物、並びにそれらの使用
IL308336A (en) 2021-05-07 2024-01-01 Alpine Immune Sciences Inc Methods of dosing and treatment with TACI-FC modulatory fusion protein
WO2023172883A1 (en) 2022-03-07 2023-09-14 Alpine Immune Sciences, Inc. Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses
WO2024011250A1 (en) 2022-07-08 2024-01-11 Viromissile, Inc. Oncolytic vaccinia viruses and recombinant viruses and methods of use thereof
WO2024077018A2 (en) 2022-10-04 2024-04-11 Alpine Immune Sciences, Inc. Methods and uses of taci-fc fusion immunomodulatory protein

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US5206353A (en) 1988-07-23 1993-04-27 The United States Of America As Represented By The Department Of Health And Human Services CD-4/cytotoxic gene fusions
EP0487587A1 (en) * 1989-08-18 1992-06-03 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
US5126132A (en) 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer
DE69233186T2 (de) * 1991-05-06 2004-06-03 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Karcinoembryonale antigen expremierende rekombinante viren und methoden ihrer anwendung
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
WO1994024267A1 (en) 1993-04-20 1994-10-27 Robinson, William, S. Methods and materials for treatment of individuals infected with intracellular infectious agents
US6969609B1 (en) * 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof

Also Published As

Publication number Publication date
PT784483E (pt) 2001-05-31
ATE197765T1 (de) 2000-12-15
JP2004222726A (ja) 2004-08-12
DE69519521D1 (de) 2001-01-04
EP1016418A3 (en) 2004-03-03
WO1996010419A3 (en) 1996-05-17
AU688606B2 (en) 1998-03-12
CA2201587A1 (en) 1996-04-11
DE69519521T2 (de) 2001-06-28
JPH10506902A (ja) 1998-07-07
CA2201587C (en) 2002-06-25
GR3035458T3 (en) 2001-05-31
US20050063993A1 (en) 2005-03-24
EP1016418A2 (en) 2000-07-05
EP1016418B1 (en) 2009-12-30
US7368116B2 (en) 2008-05-06
JP4160612B2 (ja) 2008-10-01
JP3907698B2 (ja) 2007-04-18
JP2007105045A (ja) 2007-04-26
AU3735395A (en) 1996-04-26
US6548068B1 (en) 2003-04-15
ES2154738T3 (es) 2001-04-16
US20050186180A1 (en) 2005-08-25
JP4078319B2 (ja) 2008-04-23
EP0784483A2 (en) 1997-07-23
WO1996010419A2 (en) 1996-04-11
EP0784483B1 (en) 2000-11-29
US6893869B2 (en) 2005-05-17

Similar Documents

Publication Publication Date Title
DK0784483T3 (da) Præparat indeholdende et rekombinant virus, der udtrykker et antigen, og et rekombinant virus, der udtrykker et immunstimul
DE69536039D1 (de) Wirtszelle enthaltend ein rekombinantes Virus, welches ein Antigen exprimiert und ein rekombinantes Virus, welches ein immunstimulatorisches Molekül exprimiert
WO1996011279A3 (en) Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system
PT1975235E (pt) Vacina de poxvírus recombinante contra o circovírus porcino
MA27699A1 (fr) Vaccin contre vhc
KR900700508A (ko) 인간의 호흡기 합포체성 바이러스에 대한 당단백질 면역 단편을 함유하는 키메라(chimeric) 당단백질
CY1115749T1 (el) Κυκλοϊος χοιρων, νουκλεϊνικα οξεα, πολυπεπτιδια και εμβολια
NO20012223L (no) Nukleotid- og proteinsekvenser for NOGO-genene og fremgangsmåter basert derpå
ATE430200T1 (de) Impstoff gegen den für atemwegs- und reproduktionserkrankungen beim schwein verantwortlichen virus
PT93393A (pt) Processo para a preparacao de vacinas e de agentes de diagnostico que contem regioes imunogenicas de proteina e7do virus do papiloma humano do tipo 16 ou anticorpos suscitados contra estas regioes
MXPA02011545A (es) Virus del sindrome respiratorio y reproductor porcino (peesv), vacuna recombinante para el virus de la viruela.
EA200100302A1 (ru) Способы и композиции для протективной и терапевтической генетической иммунизации
DK22389D0 (da) Fremgangsmaade og middel til beskyttelse mod sygdomme foraarsaget af mikroorganismer, navnlig mycoplasma
DE19580890D2 (de) Lebendvakzine zur Behandlung von Tumorerkrankungen
PT712926E (pt) Virus da doenca pancreatica do peixe
ATE285239T1 (de) Dna enthaltende impfstoffen
RU97106340A (ru) Днк, кодирующая папиломавирус типа 6а человека
PT868522E (pt) Virus recombinante de poxvirus - virus da peritonite infecciosa felina, suas composicoes e metodos para a sua preparacao e utilizacao
MY101874A (en) Vaccine
DE60035485D1 (de) IDENTIFIZIERUNG VON SPEZIFISCHEN DIFFERENZIELL EXPRIMIERTEN ANTIGENEN AUS MYCOBACTERIUM UND MEDIZINISCHE VERWENDUNG DER MYCOBAKTERIUMPROTEINE Rv0068 UND Rv3407
ATE323772T1 (de) Regulatorische sequenzen des humanen mcp-1 gens
FR2792639B1 (fr) Nouveaux immunogenes anti-vih (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida
ATE210990T1 (de) Therapeutischer viraler wirkstoff, welcher das fortschreiten von tumoren stoppt
FI945110A (fi) Tippuribakteerien rokotteiden valmistusmenetelmä
MX9708615A (es) Terapia de genes animales.